Key players in the single-cell analysis market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), BD (US), ...

Shares of Danaher Corp. DHR slipped 8.15% to $181.77 Friday, on what proved to be an all-around poor trading session for the ...

DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies.

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

Partners in Financial Planning has jumped into Danaher with a $433,000 stake, joining a chorus of institutions reshuffling ...

Danaher Corp. closed 29.75% below its 52-week high of $281.70, which the company achieved on August 1st.

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Danaher (DHR – Research Report) on April 1 and set a price target of $270.00. The ...

Out of all of the options we uncovered, 15 are puts, for a total amount of $1,238,077, and there was 1 call, for a total ...

McDonald, a veteran of more than 35 years in medtech, most recently served as CEO of LivaNova. Over six years there, he drove ...

In February the company had announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, ...

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Oracle Corp.